Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 6/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30104097 | 0.76 | PGR (0.44) | DPP4CYP2A6PGR | |
| SCHEMBL22733865 | 0.75 | KCNH2 (0.48) | ERN1KCNH2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL21654139 | 0.74 | KCNH2 (0.41) | ERN1KCNH2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL21654340 | 0.74 | KCNH2 (0.38) | ERN1KCNH2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL379478 | 0.74 | HDAC6 (0.44) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL6194738 | 0.72 | LMNA (0.46) | ERN1CYP2E1CYP3A4CYP2A6CYP2C9 | |
| SCHEMBL5852 | 0.72 | HDAC2 (0.56) | DPP4ERN1KCNH2CYP2E1CYP3A4 | |
| SCHEMBL18876430 | 0.72 | KCNH2 (0.46) | ERN1KCNH2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL7396854 | 0.72 | KCNH2 (0.46) | ERN1KCNH2CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL7396852 | 0.72 | KCNH2 (0.46) | ERN1KCNH2CYP2E1CYP3A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100343256-C | Biaryl substituted diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | CN | claimed |
| CN-1678615-A | Biaryl substituted diazabicycloalkanes as nicotinic acetylcholine antagonists | ASTRAZENECA AB (SE) | 2005-10-05 | — | — | CN | claimed |
| EP-1539765-A1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | claimed |
| WO-2004016617-A1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | claimed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
| WO-2013086131-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-13 | — | — | WO | disclosed |
| CN-100343256-C | Biaryl substituted diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | CN | disclosed |
| CN-1678615-A | Biaryl substituted diazabicycloalkanes as nicotinic acetylcholine antagonists | ASTRAZENECA AB (SE) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | HAVCR2, HDLBP, HSP90B1 | DPP4 1599/4885ERN1 1739/4885KCNH2 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.